Immunogenicity and reactogenicity of indigenously produced MMR vaccine

Area of Science:

• Pediatric Infectious Diseases
• Vaccinology
• Immunology

Background:

• The development of indigenous vaccines is crucial for public health.
• Understanding the immunogenicity and reactogenicity of new vaccine formulations is essential.

Purpose of the Study:

• To evaluate the immunogenicity and reactogenicity of an indigenously produced Measles, Mumps, and Rubella (MMR) vaccine.
• To assess the booster effect of MMR immunization on measles seroconversion in children.

Main Methods:

• A longitudinal follow-up study involving 89 children (15-24 months) for immunogenicity and 866 subjects for reactogenicity.
• ELISA was used to measure IgG and IgM antibodies pre- and post-vaccination (1 and 4 weeks).
• Clinical follow-up was conducted at multiple time points up to 6 months post-immunization.

Main Results:

• Significant increases in IgG positivity were observed: measles (75% to 100%), mumps (12% to 92%), and rubella (13% to 99%) four weeks post-vaccination.
• The vaccine exhibited low reactogenicity, with only mild side effects reported, including pain, fever, cough, and transient rash.
• Measles seroconversion rates improved in children previously immunized for measles, indicating a booster effect.

Conclusions:

• The indigenously manufactured MMR vaccine demonstrates excellent immunogenicity and favorable reactogenicity profiles.
• The vaccine is effective in inducing protective antibody levels against measles, mumps, and rubella.
• A booster effect on measles seroconversion was noted in previously immunized children, highlighting the vaccine's comprehensive impact.